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SUMMARY
SU6656, a Src kinase inhibitor, was reported to in-
crease fat oxidation and reduce body weight in
mice, with proposed mechanisms involving AMP-
activated protein kinase (AMPK) activation via inhibi-
tion of phosphorylation of either LKB1 or AMPK by
the Src kinase, Fyn. However, we report that AMPK
activation by SU6656 is independent of Src kinases
or tyrosine phosphorylation of LKB1 or AMPK and
is not due to decreased cellular energy status or
binding at the ADaM site on AMPK. SU6656 is a
potent AMPK inhibitor, yet binding at the catalytic
site paradoxically promotes phosphorylation of
Thr172 by LKB1. This would enhance phosphoryla-
tion of downstream targets provided the lifetime of
Thr172 phosphorylation was sufficient to allow
dissociation of the inhibitor and subsequent catal-
ysis prior to its dephosphorylation. By contrast,
sorafenib, a kinase inhibitor in clinical use, activates
AMPK indirectly by inhibiting mitochondrial meta-
bolism and increasing cellular AMP:ADP and/or
ADP:ATP ratios.
INTRODUCTION
AMP-activated protein kinase (AMPK) is a sensor of cellular en-
ergy status. It exists in eukaryotes as heterotrimeric complexes
comprising catalytic a and regulatory b and g subunits (Hardie
et al., 2016; Ross et al., 2016b), occurring in mammals as multi-
ple isoforms (a1/a2; b1/b2; g1/g1/g3) (Stapleton et al., 1996;
Thornton et al., 1998; Cheung et al., 2000). AMPK can be acti-
vated >100-fold by phosphorylation at a conserved threonine
(Thr172) within the activation loop of the kinase domain. The
major upstream kinase phosphorylating Thr172 is a complex
containing LKB1, which also phosphorylates and activates a
family of 12 AMPK-related kinases; Thr172 can also be phos-
phorylated by the Ca2+-activated kinase, CaMKK2 (Hardie
et al., 2016; Ross et al., 2016b). The AMPK-b subunits contain
a carbohydrate-binding module (b-CBM), and a cleft between
this domain and the small lobe of the a subunit kinase domain
forms the allosteric drug andmetabolite (ADaM) site (Langendorf
and Kemp, 2015), where activators such as the natural product,
salicylate, and the synthetic compounds, 991 and A769662, bind
(Hawley et al., 2012; Xiao et al., 2013). The g subunits contain up
to three sites at which the regulatory nucleotides AMP, ADP, and
ATP can bind in competition (Xiao et al., 2007; Chen et al., 2012).
Binding of AMP or ADP promotes net Thr172 phosphorylation by
enhancing phosphorylation and inhibiting dephosphorylation
(Oakhill et al., 2011; Xiao et al., 2011), while binding of AMP
causes further allosteric activation, at least with g1 and g2 com-
plexes (Ross et al., 2016a). AMPK is therefore activated by
stresses that interfere with ATP synthesis or accelerate ATP con-
sumption, causing increases in cellular AMP:ATP and ADP:ATP
ratios. It acts to restore cellular energy balance by switching
on catabolic pathways that generate ATP, while switching off
ATP-consuming processes.
Most studies suggest that LKB1 complexes are constitutively
active, with Thr172 phosphorylation being regulated instead by
binding of adenine nucleotides to AMPK (Hardie et al., 2016;
Ross et al., 2016b). However, it has been proposed that LKB1
is regulated by tyrosine phosphorylation by members of the
Src kinase family. Following observations of metabolic changes
in Fyn knockout mice (Bastie et al., 2007), treatment of mice with
the Src kinase inhibitor SU6656 increased fatty acid oxidation
associated with increased phosphorylation of AMPK and its
downstream target acetyl-CoA carboxylase (ACC) in skeletal
muscle (Yamada et al., 2010). Treatment of C2C12 cells with
SU6656 caused translocation of GFP-LKB1 from nucleus to
cytoplasm, while overexpression of Fyn had the opposite effect.
Finally, Fyn was found to phosphorylate LKB1 on Tyr261 and
Tyr365, leading to a model in which LKB1 tyrosine phosphoryla-
tion causes nuclear retention, reducing its ability to activate cyto-
plasmic AMPK. Another group reported that the Src kinase Lck
phosphorylated LKB1 on Tyr36, as well as Tyr261/365 (Cao
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et al., 2011). More recently, Yamada et al. (2016) proposed a
different mechanism in which Fyn phosphorylates Tyr436 on
the AMPK-a subunit, causing its direct inhibition.
We now confirm that SU6656 activates AMPK but show that
it does this not by modulating tyrosine phosphorylation of
LKB1 or AMPK but, surprisingly, by direct interaction with the
AMPK kinase domain. Recently sorafenib, another kinase inhib-
itor already licensed for treatment of some cancers (Gadaleta-
Caldarola et al., 2015), was reported to activate AMPK in tumor
cell lines (Fumarola et al., 2013; Groenendijk et al., 2015). We
show that, in contrast to SU6656, sorafenib activates AMPK indi-
rectly by inhibiting mitochondrial metabolism and increasing
cellular AMP:ATP and ADP:ATP ratios.
RESULTS
SU6656 Activates AMPK but Not AMPK-Related Kinases
Treatment of HEK293 cells with increasing concentrations of
SU6656 caused activation of AMPK that correlated with Thr172
phosphorylation; it also increased phosphorylation of one down-
stream target, ACC, but not another, Raptor. Another AMPK acti-
vator, berberine, caused a much smaller degree of AMPK activa-
tion and Thr172 phosphorylation, yet had similar effects on ACC
phosphorylation and did promote Raptor phosphorylation (Fig-
ure 1A). By immunoprecipitatingwith isoform-specific antibodies,
SU6656 was found to activate AMPK complexes containing the
a1, a2, b1, and b2 subunit isoforms (Figure 1B). In HEK293 cells,
AMPK occurs primarily as g1 complexes (Hawley et al., 2010),
but we show later (Figure 3A) that g2 complexes can also be acti-
vated by SU6656.
If SU6656 acts by blocking phosphorylation of LKB1 by Fyn
and promoting migration of LKB1 to the cytoplasm (Yamada
et al., 2010), the AMPK-related kinases (ARKs) downstream of
LKB1 should also be activated. All of the ARKs except BRSK1
and BRSK2 are expressed in the LKB1-null HeLa cell line,
although they are only active if LKB1 is re-expressed (Lizcano
et al., 2004). While SU6656 robustly activated AMPK in HeLa
cells expressing LKB1, none of the ARKs assayed were acti-
vated (Figure 1C).
AMPK Activation Does Not Require Src Kinases or LKB1
Tyrosine Phosphorylation
The results in Figure 1C provided the first hint that AMPK activa-
tion by SU6656 might not be working via the previously sug-
gested mechanism involving LKB1 phosphorylation by Fyn.
Consistentwith this, PP2, amore selective inhibitor ofSrc kinases
than SU6656 (Bain et al., 2007) although not specific for them
(Brandvold et al., 2012), had no effect on AMPK activity or
Thr172 phosphorylation in HEK293 cells. PP2 and SU6656 both
reduced phosphorylation of Erk1/Erk2, as expected for Src inhib-
itors (Figure 2A).Wenext tested the effect of SU6656 in SYFcells,
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Figure 1. SU6656 Activates AMPK but Not AMPK-Related Kinases
(A) HEK293 cells were incubated with the indicated concentrations of SU6656
or berberine (300 mM) for 1 hr; total AMPK activity was assayed in immuno-
precipitates (top; mean ± SEM, n = 4), and phosphorylation of AMPK (Thr172),
ACC (Ser80), and Raptor (Ser792) analyzed bywestern blotting (bottom; n = 2).
(B) HEK293 cells were incubatedwith 100 mMSU6656 (1 hr), AMPK complexes
containing a1, a2, b1, and b2 immunoprecipitated using isoform-specific
antibodies, and AMPK activity measured (mean ± SEM, n = 4).
(C) HeLa cells stably expressing LKB1 (Fogarty et al., 2010) were incubated
with 100 mM SU6656 for 1 hr, AMPK or individual ARKs immunoprecipitated,
and kinase assays carried out (antibodies that distinguish MARK2/MARK3
were not available, so they were assayed together). Results are means ± SEM
(n = 2).
In all panels, asterisks indicate significant differences from controls without
SU6656. *p < 0.05, **p < 0.01, ****p < 0.0001.
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which are mouse embryo fibroblasts (MEFs) with null alleles for
Src, Yes, and Fyn, the three Src kinases expressed in MEFs
(Klinghoffer et al., 1999). PP2 still had no effect on AMPK, but
now also had no effect on Erk1/2, as expected. However,
SU6656 still activated and increased Thr172 phosphorylation of
AMPK (Figure 2B). Surprisingly, it also inhibited Erk1/2 phosphor-
ylation, suggesting additional Src kinase-independent effects.
We next transiently transfected DNAs encoding GFP, or
GFP-tagged wild-type (WT), Y261F/Y365F (FF), or Y36F/
Y261F/Y365F (FFF) mutants of LKB1 into HeLa cells, which
lack endogenous LKB1. AMPK was activated (Figure 2C) and
phosphorylated on Thr172 (Figure S1, Supplemental Informa-
tion) by SU6656 treatment equally in cells expressing the WT,
FF, or FFF mutants, although not with the GFP control.
To test whether AMPK activation by SU6656 was due to inhi-
bition of phosphorylation of Tyr436 on the AMPK-a subunits by
Fyn (Yamada et al., 2016), we expressed FLAG-tagged WT or
Y436F mutant human AMPK-a2 in HEK293 cells, treated with
various activators and measured AMPK activity in anti-FLAG im-
munoprecipitates. SU6656, phenformin (which acts by inhibiting
mitochondrial complex I and increasing AMP/ADP) and A23187
(an ionophore that increases intracellular Ca2+ and activates
CaMKK2) all activated AMPK, and these responses were un-
affected by the Y436F mutation (Figure 2D).
Sorafenib, but Not SU6656, Activates AMPK
by an AMP-Dependent Mechanism
The next possibility was that, like several other AMPK-activating
drugs, SU6656 inhibits mitochondrial ATP synthesis, and thus
activates AMPK indirectly by increasing cellular AMP/ADP. To
test this, we used cell lines inducibly expressing either WT
AMPK-g2 or an AMP/ADP-resistant R531G (RG) mutant (Hawley
et al., 2010). As expected, berberine (an inhibitor of mitochon-
drial complex I) activated AMPK in the WT but not the RG cells,
while A769662 (which directly binds AMPK at the ADaM site;
Xiao et al., 2013), activated AMPK in both. SU6656 behaved
like A769662 in that it activated AMPK and enhanced Thr172
phosphorylation in both WT and RG cells, although the effects
were somewhat smaller in the latter (Figure 3A). There were no
significant effects of SU6656 on cellular AMP:ATP or ADP:ATP
ratios in WT or RG cells, although they were robustly increased
by berberine, to a greater extent in RG than in WT cells (Fig-
ure 3B). There were no effects of SU6656 on cellular oxygen up-
take, unlike berberine. Subsequent addition of the uncoupler
2,4-dinitrophenol (DNP), which prevents the respiratory chain
from being limited by ADP supply, increased oxygen uptake
identically in control and SU6656-treated cells but had no effect
following berberine, as expected for a complex I inhibitor
(Figure S2).
We also examined the effects of sorafenib, another kinase in-
hibitor reported to paradoxically activate AMPK (Fumarola et al.,
2013; Groenendijk et al., 2015). Sorafenib activated AMPK and
promoted Thr172 and ACC phosphorylation in HEK293 cells
(Figure 3C), with significant effects at 10 and 30 mM (peak plasma
sorafenib in human clinical trials was 6–20 mM; Strumberg et al.,
2007). Sorafenib also increased cellular AMP:ATP and ADP:ATP
ratios to a similar or even greater extent than phenformin (Fig-
ure 3D). Moreover, like phenformin (but unlike SU6656), it rapidly
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Figure 2. AMPK Activation by SU6656 Does
Not Require an Src Family Kinase or Tyrosine
Phosphorylation of Either LKB1 or AMPK
(A) HEK293 cells were incubated with the indicated
concentrations of SU6656 or PP2 for 1 hr and AMPK
activity assayed. Top: AMPK activity (mean ± SEM,
n = 4); bottom: western blots showing phosphory-
lation of Thr172 on AMPK, and of ERK1/2, in cells
treated with DMSO (control), SU6656 (100 mM), or
PP2 (100 nM) (n = 2).
(B) As (A), but in SYF cells.
(C) HeLa cells were transfected with DNAs encoding
GFP alone, or GFP fused to WT, Y261F/Y365F (FF),
or Y36F/Y261F/Y365F (FFF) mutants of LKB1; cells
were treated with increasing concentrations of
SU6656 for 1 hr and AMPK activity determined
(mean ± SEM, n = 4). See also Figure S1.
(D) HEK293 cells were transfected with DNAs en-
coding FLAG-tagged AMPK-a2 with or without a
Y436F mutation. Cells were incubated with DMSO
(control), 100 mM SU6656, 10 mM phenformin, or
10 mM A23187 for 1 hr; AMPK complexes were
immunoprecipitated using anti-FLAG antibody and
assayed. The top panels show kinase activities
(mean ± SD, n = 3); the bottom panels show blots
from the same experiment (n = 2).
In all panels, asterisks indicate significant differ-
ences from DMSO controls; in (D), there were no
significant differences between the WT and Y463F
mutant. **p < 0.01, ****p < 0.0001.
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inhibited cellular oxygen uptake at concentrations from 3 to
30 mM (Figure 3E). We also examined its effects in cells express-
ing the AMPK-g2 RG mutant, generated by transient transfec-
tion. Neither AMPK activity nor Thr172 phosphorylation were
significantly elevated by sorafenib in the RG cells, unlike the
WT cells (Figure 3F).
SU6656 Does Not Activate AMPK by Binding at the
ADaM Site
We next tested whether SU6656 activates AMPK by binding at
the ADaM site. Another recently described activator, MT 63-
78, may bind this site since, like A769662 and salicylate, it is a
more potent activator of AMPK complexes containing b1 rather
than b2 (Zadra et al., 2014). In crystal structures, Lys40 and
Lys42 in a1 (Lys29/Lys31 in a2) are either directly involved in in-
teractions with the activating ligand in the ADaM site or form
electrostatic interactions with the autophosphorylated side
chain of Ser108 in AMPK-b1, thus stabilizing the site; mutation
of both lysines abolished activation by A769662 (Xiao et al.,
2013; Li et al., 2015). We therefore expressed WT or single
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(A) Top: HEK293 cells expressing wild-type (WT)
AMPK-g2 or the R531G (RG) mutant were treated
for 1 hr with SU6656 at 10, 30 or 100 mM (S10, S30,
S100), 300 mM berberine (berb) or 300 mM A769662
(A76) and AMPK assayed (mean ± SEM, n = 4);
bottom: blots of Thr172 phosphorylation and total
AMPK-a in cells (n = 2) incubated with DMSO or
100 mM SU6656 for 1 hr.
(B) WT or RG cells were treated as in (A) and nu-
cleotides extracted for analysis (mean ± SD, n = 3).
(C) Effects of incubation (1 hr) of WT HEK293 cells in
increasing concentrations of sorafenib, A769662
(300 mM) or phenformin (10 mM) on AMPK activity
(top, mean ± SEM, n = 3) and on phosphorylation of
Thr172 and ACC (bottom).
(D) Effects of incubation of WT HEK293 cells (1 hr) in
increasing concentrations of sorafenib, A769662
(300 mM) or phenformin (10 mM) on cellular
AMP:ATP/ADP:ATP ratios (mean ± SD, n = 3).
(E) (See also Figure S2) Time courses of cellular
oxygen uptake before and after addition of the
indicated concentrations of sorafenib (SO, mM),
SU6656 (100 mM) or phenformin (PHEN, 10 mM)
(mean ± SEM, n = 4).
(F) Effect of various concentrations of sorafenib
or phenformin (10 mM) on activation (top,
mean ± SEM, n = 3) or phosphorylation (bottom) of
AMPK in cells expressing wild-type AMPK-g2 (WT)
or the R531G mutant AMPK-g2 (RG).
In all panels, asterisks show significant differences
from DMSO controls (ns, not significant). In (B),
daggers (y) show significant differences between
results in WT and RG cells. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001, yyyyp < 0.0001.
(K40A, K42A) or double (K40A/K42A, AA)
a1 mutants in the context of the human
a1b1g1 complex (Figure 4A). Bacterially
expressed AMPK complexes are not phos-
phorylated on Thr172 but can be allosterically activated by
A769662 as long as b1-Ser108 is autophosphorylated (Scott
et al., 2014a), which was the case with the WT and all mutants
(Figure 4B). As expected, A769662 caused a large allosteric acti-
vation of theWT complex (activation = 38 ± 1-fold, concentration
causing half-maximal effect [EC50] = 1.0 ± 0.1 mM [±SEM]).
The single K40A or K42A mutations exhibited greatly reduced
activation by A769662, while the double (AA) mutation abolished
it (Figure 4C). Similar results were obtained with MT 63-78 (WT:
activation = 16 ± 1-fold, EC50 = 23 ± 4 mM) (Figure 4D). By
contrast, AMP still allosterically activated both the single and
double mutants (Figure 4E). Although maximal activation
was slightly reduced by the mutations (3.3 ± 0.3, 2.6 ± 0.1,
2.2 ± 0.1, and 2.4 ± 0.2-fold activation for WT, K40A, K42A,
and AA mutant, respectively), there were no significant effects
on the EC50 for AMP (20 ± 7, 19 ± 6, 23 ± 6, and 18 ± 8 mM).
We next expressed the FLAG-tagged WT or AA mutant of
AMPK-a1 by transient transfection in HEK293 cells, treated
with various agents, and measured AMPK activity in anti-FLAG
immunoprecipitates. In Figure 4F, the results are expressed as
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absolute activities and are accompanied by blots showing
Thr172 phosphorylation. For reasons that remain unclear, the
AA mutation caused a 3- to 4-fold drop in kinase activity and
Thr172 phosphorylation in the DMSO control, which is why the
activities are also expressed relative to the DMSO control in Fig-
ure 4G. As expected, A769662, berberine, phenformin, troglita-
zone, oligomycin, and SU6656 activated AMPK and caused
Thr172 phosphorylation with the WT complexes, and the AA
mutation completely prevented the effect of A769662. More sur-
prisingly, the effects of agents that increase cellular AMP:ATP,
either by inhibiting the respiratory chain (berberine, phenformin,
troglitazone) or the F1 ATP synthase (oligomycin), were also
abolished by the AA mutation (note that any allosteric effects
are lost during immunoprecipitation; any effects remaining are
due to changes in Thr172 phosphorylation). However, SU6656
still caused a 3-fold increase in activity and Thr172 phosphoryla-
tion with bothWT and AAmutant, despite the lower basal activity
in the latter (Figure 4G), confirming that it acts by binding to
site(s) distinct from either A769662 or AMP.
SU6656 and AMP Promote Thr172 Phosphorylation by
Binding to the Catalytic Site: Studies in Cell-Free
Systems
Since SU6656 activation did not require functional g-subunit or
ADaM sites, this left the catalytic site as the most likely binding
site. Indeed, SU6656 inhibits AMPK as effectively as Src (Bain
et al., 2007). To examine this in more detail, we initially used a
purified preparation of rat liver AMPK (Hawley et al., 1996) and
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Figure 4. MT 63-78, but Not SU6656, Acti-
vates AMPK by Binding at the ADaM Site
(A) Coomassie blue-stained gel of purified, bacte-
rially expressed human a1b1g1 complex, WT or
with K40A, K42A, or K40A/K42A (AA) mutations in
a1; ArnA is a contaminating protein from Escher-
ichia coli identified by peptide mass fingerprinting.
(B) Western blotting of the same preparations as
in (A).
(C) Allosteric activation of WT and mutant a1b1g1
complexes (phosphorylated on b1-Ser108 but not
a1-Thr172) by A769662. Data are expressed rela-
tive to the basal activity in the absence of activator
and were fitted to the equation: Y = 1 + ((Activa-
tion  1) 3 X)/(EC50 + X), where Y is activity, X is
activator concentration, Activation is the maximal
activation and EC50 is the concentration giving half-
maximal activation. Parameters for the WT are
quoted in the main text, the Activation and EC50
values for the K40A, K42A, and AA mutants were
18 ± 0.7-fold, 21 ± 0.6-fold, and 1.0 ± 0.03-fold, and
4 ± 0.7, 14 ± 0.6, and 0.001 ± 0.002 mM, respec-
tively; continuous lines are theoretical curves drawn
using these parameters.
(D) Allosteric activation of WT and mutant a1b1g1
complexes by MT 63-78, curve fitting as for (C).
Parameters for the WT are quoted in the main text,
the Activation and EC50 for the K40A mutant were
3.4 ± 0.1-fold and 7 ± 2 mM; fitting for the K42A and
AA mutants did not yield sensible values.
(E) Allosteric activation of WT and mutant a1b1g1
complexes by AMP. Data were fitted to the
equation for activation/inactivation by AMP
(Gowans et al., 2013). Best-fit values for activation
and EC50 are given in the main text; values for
IC50 were 8.5 ± 4.1, 6.1 ± 1.9, 11.9 ± 3.8, and
8.8 ± 4.6 mM (WT, K40A, K42A, and AA); contin-
uous lines are theoretical curves drawn using these
parameters.
(F) Activation of WT and AA mutant by various
AMPK activators in HEK293 cells. Cells were
transfected with DNAs encoding FLAG-tagged
AMPK-a1 (WT or AA mutant) and treated with
A769662 (300 mM), berberine (300 mM), phenformin
(10 mM), troglitazone (100 mM), oligomycin (1 mM),
or SU6656 (100 mM) for 1 hr. FLAG-tagged com-
plexes were isolated by immunoprecipitation and
AMPK activity determined (mean ± SEM, n = 2). Asterisks indicate significant differences from DMSO controls. The bottom panel shows western blotting of the
anti-FLAG precipitates. ****p < 0.0001; ns, not significant.
(G) Same experiment as (F), but results expressed relative to DMSO controls. ****p < 0.0001.
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conducted assays at 2 mM ATP, when AMP causes a substantial
allosteric activation (>5-fold) (Gowans et al., 2013). Under these
conditions, SU6656 inhibited both basal and AMP-stimulated ac-
tivity at concentrations above 1 mM, suggesting that it bound at
the catalytic site rather than the g subunit (Figure 5A). We then
switched to the isolated a2 kinase domain (a2-KD, residues
1–310) expressed in bacteria andphosphorylated usingCaMKK2.
As expected, inhibition of the a2-KD by SU6656 was competitive
with ATP, since the data gave good fits to an equation for compet-
itive inhibition (Figure 5B) with Vmax = 141 ± 1 nmol/min/mg,
KmATP = 151 ± 7 mM, and KiSU6656 = 0.17 ± 1 mM.
In a crystal structure of the human a2b1g1 complex (Xiao
et al., 2013), the side chain of Ala156 in a2-KD interacts
with the kinase inhibitor staurosporine in the catalytic site,
while in a structure of CaMKIId with bound SU6656 (Rellos
et al., 2010), the equivalent residue interacts with the sulfon-
amide group of SU6656. We therefore expressed the a2-KD
as the WT or an A156T (AT) mutant and phosphorylated
both using CaMKK2. Figure 5C shows that WT a2-KD was in-
hibited by SU6656 (IC50 = 0.22 ± 0.02 mM), while inhibition
was almost 10-fold less potent with the AT mutant (IC50 =
1.7 ± 0.3 mM).
We next used unphosphorylated a2-KD and tested the effect
of SU6656 on its activation and phosphorylation by LKB1. Con-
centrations of SU6656 up to 10 mM promoted activation of WT
a2-KD by LKB1 by 1.9 ± 0.2-fold and increased Thr172
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Figure 5. SU6656 Promotes AMPK Activa-
tion by Binding to the Catalytic Site: Studies
in Cell-Free Assays
(A) Effect of increasing concentrations of SU6656 ±
1 mM AMP in the presence of 2 mM ATP on the
activity of purified rat liver AMPK.
(B) Effect of ATP concentration on kinase activity of
a2-KD in the presence of increasing concentrations
of SU6656. Results (mean, n = 2) were fitted to the
equation Y= (Vmax3 X)/(Km3 (1 + I/Ki) + X), where
Y is the activity, X is the ATP concentration, I is the
concentration of SU6656, and Ki is the inhibitory
constant for SU6656. The curves were generated
using this equation with the best-fit values of Vmax,
Km, and Ki (shared between all four curves) quoted
in the main text.
(C) Inhibition of phosphorylated a2-KD (WT or AT
mutant) by SU6656. Results (mean ± SEM, n = 2)
were fitted to the equation Y = 100  (100 3 X/
(IC50 + X)); curves were generated using this
equation with values for IC50 quoted in the main
text. The reduced inhibition at 10 mM SU6656 may
be due to the inhibitor coming out of solution, so
those data were not used for curve fitting.
(D and E) Effect of increasing concentrations of
SU6656 on activity (D) and Thr172 phosphorylation
(E) induced by LKB1 with unphosphorylated a2-KD
(WT/AT mutant). Results in (D) are mean ± SEM
(n = 3); and were fitted to same equation as Fig-
ure 4C. Curves were generated using this equation
with values for Activation and EC50 of WT quoted in
the main text, and values of 1.07-fold and 0.07 mM
for the AT mutant. See also Figure S3.
(F) Effect of AMP (2 mM) and SU6656 on inactiva-
tion of AMPK by PP2Ca in the presence of 5 mM
ATP. Results are mean ± SEM (n = 3); asterisks
indicate results significantly different from controls
with PP2Ca but without AMP or SU6656.
(G) Effects of AMP or SU6656 on activation (top)
and Thr172 phosphorylation (bottom) by LKB1 of
AMPK-g1 complexes expressed in HeLa cells.
FLAG-tagged AMPK-g1, either wild-type (WT) or
R299G mutant (RG), was expressed in HeLa cells
and AMPK complexes precipitated using anti-
FLAG antibody. The complexes (which have low
basal phosphorylation due to lack of LKB1 in
HeLa cells) were incubated with or without a
limiting amount of LKB1, AMP (200 mM) or
SU6656 (3 mM) for 10 min and AMPK activity
determined.
Results are mean ± SEM (n = 6); asterisks and daggers indicate significant differences from controls without LKB1 and without AMP/SU6656, respectively.
***p < 0.001, ****p < 0.0001, yyyyp < 0.0001; ns, not significant. The lower panel shows western blots of single incubations.
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phosphorylation (Figures 5D and 5E), while both effects were
almost abolished by the AT mutation. There was no effect of
SU6656 when LKB1 was assayed using an alternative peptide
substrate (Figure S3), confirming that it acts by binding to
AMPK rather than to LKB1. The half-maximal effect of SU6656
on a2-KD activation was at 0.20 ± 0.02 mM, close to the IC50
for inhibition of catalytic activity (0.22 ± 0.02 mM).
To test whether SU6656 binding inhibited Thr172 dephos-
phorylation, we used bacterially expressed a2-KD or a full-length
a2b2g1 complex, both of which had been phosphorylated using
CaMKK2. Figure 5F shows that protein phosphatase PP2Ca
caused inactivation of both constructs, and that this was
abolished by the presence of AMP using the a2b2g1 complex,
but not the a2-KD, as expected. However, concentrations of
SU6656 up to 10 mM did not protect against inactivation using
either construct.
We also expressed FLAG-tagged AMPK-g1 in HeLa cells,
either the WT or an R299G (RG) mutation (equivalent to R531G
in AMPK-g2), which prevents AMP binding at the critical site 3
(Jensen et al., 2015). The AMPK complexes generated were
precipitated with anti-FLAG antibody and used as substrates
for LKB1 in cell-free assays. Both AMP and SU6656 promoted
activation and increased Thr172 phosphorylation by LKB1, using
complexes containingWT g1. However, while the effects of AMP
were abolished by the RG mutation, the effects of SU6656 were
preserved (Figure 5G). Note that a1 is slightly larger than a2 in
humans (64.0 versus 62.3 kDa), and the two isoforms can be
resolved by SDS-PAGE.
SU6656 and AMP Promote Thr172 Phosphorylation by
Binding to the Catalytic Site: Studies in Intact Cells
We next expressed an FLAG-tagged a1 kinase domain (a1-KD,
residues 1–312) by transient transfection in HEK293 cells, treated
the cells with various AMPKactivators, and then assayed both the
expresseda1-KD (precipitated using anti-FLAG) and endogenous
full-length a1 complexes (precipitated using anti-a1 antibodies
recognizing an epitope outside the a1-KD). SU6656 increased
kinase activity (Figure 6A) and Thr172 phosphorylation (Figure 6B)
with both the full-length endogenous a1 complexes and the
expressed a1-KD. This was also observed with A23187, as ex-
pected since this ionophore increases intracellular Ca2+ and acti-
vates the alternate upstream kinase CaMKK2. By contrast, three
activators that work by increasing cellular AMP/ADP (phenformin,
berberine, and troglitazone) all failed to activate or cause Thr172
phosphorylation of the a1-KD while doing this with the endoge-
nous complexes, consistent with the fact that only the latter
have AMP/ADP binding sites on the g subunit. A769662 is pri-
marily an allosteric activator (Goransson et al., 2007; Scott
et al., 2014a) and only has modest effects on Thr172 phos-
phorylation, particularly with g1 complexes (Ross et al., 2016a).
Although there may have been a small effect of A769662 on the
activity of immunoprecipitated full-length a1 complexes in Fig-
ure 6A, it was not statistically significant.
These results showed that only the kinase domain was
required for SU6656 to activate AMPK in intact cells. To confirm
that it acted by binding at the catalytic site, we expressed FLAG-
tagged full-length AMPK-a1 either as the WT or the AT mutant.
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B Figure 6. SU6656 Promotes AMPK Activa-
tion by Binding to the Catalytic Site: Studies
in Intact Cells
(A) FLAG-tagged a1 kinase domain (a1-KD, 1–312)
was expressed by transient transfection in HEK293
cells and the cells treated with SU6656 (100 mM),
A23817 (10 mM), A769662 (300 mM), phenformin
(10 mM), berberine (100 mM), or troglitazone
(100 mM) for 1 hr. The a1-KD was precipitated using
anti-FLAG and endogenous AMPK complexes
using anti-a1 antibody, and activity determined.
Results (mean ± SD, n = 2) are expressed relative to
activities in DMSO controls.
(B) Western blots (n = 2) using the indicated anti-
bodies; samples from experiment in (A).
(C) DNAs encoding FLAG-tagged AMPK-a1 (WT or
AT mutant) were expressed by transient trans-
fection in HEK293 cells, the cells treated with
increasing concentrations of SU6656 for 1 hr,
AMPK complexes precipitated with anti-FLAG, and
activity measured. Results (mean ± SD, n = 3) are
expressed relative to the DMSO control. The ab-
solute activities of the WT and AT mutant were
0.14 ± 0.01 (WT) and 0.12 ± 0.01 nmol/min/mg
(mean ± SEM, n = 3); in separate experiments we
showed that the AT mutant was stimulated 2.6-fold
by 200 mM AMP, similar to the WT.
(D) As (C), but cells were treated with phenformin
(10 mM), A23187 (10 mM), A769662 (300 mM), or
SU6656 (100 mM) for 1 hr. Results (mean ± SD, n = 3)
are expressed relative to the DMSO control.
**p < 0.01, ***p < 0.001, ****p < 0.0001, yyyp < 0.001;
ns, not significant.
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Figure 6C shows that the WT was robustly activated by SU6656
up to 100 mM as before, but that activation was greatly reduced
with the ATmutant, although there was a small effect at the high-
est concentration. Figure 6D shows that the WT and AT mutant
were activated equally well by the complex I inhibitor phenformin
and A23187; once again, A769662 did not cause a significant
activation in this experiment. However, activation by SU6656
was significantly reduced by the AT mutation.
Another AMPK Inhibitor, MRT199665, Also Causes
Paradoxical Activation in Cells
We wondered whether other AMPK inhibitors might have the
same paradoxical effect as SU6656. However, many known
inhibitors, including staurosporine and compound C, inhibit
LKB1 with similar potency to AMPK (see MRC Kinase Inhibitor
Database, www.kinase-screen.mrc.ac.uk/kinase-inhibitors), so
increased Thr172 phosphorylation by LKB1 in intact cells is
not observed. By searching this database, we found one other
inhibitor, MRT199665, where inhibition of LKB1 was less potent
than that of AMPK, as with SU6656. When HEK293 cells were
incubated with increasing concentrations of MRT199665, we
observed a modest increase in AMPK activity and Thr172 phos-
phorylation, more than with A769662 but much less than with
phenformin or SU6656. However, unlike SU6656, A769662, or
phenformin, MRT199665 led to inhibition of phosphorylation of
the downstream target ACC (Figure 7A). Activation of AMPK by
MRT199665 was not associated with changes in AMP:ATP or
ADP:ATP ratios (Figure 7B), so we believe that it was activating
AMPK via the same mechanism as SU6656.
DISCUSSION
Our results show that SU6656 activates AMPK but not by inhibi-
tion of phosphorylation of either LKB1 or AMPK by Fyn or
another Src family kinase as previously suggested (Yamada
et al., 2010; Yamada et al., 2016). The key evidence is: (1)
SU6656 did not activate any of the ARKs that are also LKB1-
dependent; (2) the effect was not mimicked by another Src
kinase inhibitor, PP2; (3) it was still observed in SYF cells, which
do not express any Src family kinase; (4) it was still observed in
HeLa cells expressing LKB1 with all three tyrosine residues
phosphorylated by Fyn and/or Lck mutated; (5) it was still
observed in cells expressing AMPK-a2 with a mutation (Y436F)
in the tyrosine residue proposed to be phosphorylated by Fyn
(Yamada et al., 2016); (6) it was still observed, both in cell-free
assays and intact cells, with AMPK-a1/-a2 constructs containing
only the kinase domains and therefore lacking Tyr432/436.
Although our results cast doubt on these previously proposed
mechanisms, they do not invalidate the results showing that
SU6656 activated AMPK in mice in vivo, and that this led to in-
creases in fat oxidation and decreases in fat mass (Yamada
et al., 2010), which can be explained by SU6656-mediated phos-
phorylation of ACC by AMPK. In that study, the decrease in res-
piratory quotient induced by SU6656 (indicating increased fat
oxidation) was reported to be absent in Fyn/ mice. However,
the respiratory quotient was already markedly lower in untreated
Fyn/ mice than in WT mice, suggesting that the Fyn knockout
may have already increased fatty acid oxidation by some other
mechanism, so that any further stimulation by SU6656 might
no longer be evident. The authors do not appear to have tested
whether SU6656 still activated AMPK in the Fyn knockout mice.
We initially suspected that SU6656 might activate AMPK indi-
rectly by interfering with cellular metabolism and increasing
cellular AMP or ADP, since many xenobiotics act by that mech-
anism (Hawley et al., 2010). Our results rule this out because, at
concentrations that caused robust AMPK activation, SU6656: (1)
did not increase cellular AMP:ATP/ADP:ATP ratios; (2) did not
affect cellular oxygen uptake; (3) still activated AMPK in cells ex-
pressing an AMP/ADP-insensitive mutant of the AMPK-g2 sub-
unit; (4) still promoted activation and phosphorylation by LKB1
in cell-free assays of AMPK complexes containing an AMP/
ADP-insensitive mutant of AMPK-g1. This contrasts with re-
sults obtained using another kinase inhibitor, sorafenib, which
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Figure 7. Another AMPK Inhibitor, MRT199665, Activates AMPK but
Inhibits ACC Phosphorylation in HEK293 Cells
(A) Effect of MRT199665, phenformin (10 mM), A769662 (300 mM), or SU6656
(100 mM) on AMPK activity in HEK293 cells. Cells were incubated for 60 min
and AMPK activity measured; results in the top panel are means ± SEM (n = 8),
with significant differences from the DMSO control indicated (ns, not signifi-
cant). The bottompanels showwestern blots from the same experiment (n = 2).
(B) Analysis of AMP:ATP and ADP:ATP ratios from a parallel experiment to that
in (A). Results are means ± SEM (n = 3), with significant differences from the
DMSO control indicated.
*p < 0.05, **p < 0.01, ****p < 0.0001.
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increased cellular AMP:ATP and ADP:ATP ratios, inhibited
cellular oxygen uptake, and failed to activate AMPK in cells ex-
pressing the AMP/ADP-insensitive mutant, all at therapeutically
relevant concentrations. These results show that sorafenib,
which is in clinical use (Gadaleta-Caldarola et al., 2015), acti-
vates AMPK indirectly by inhibiting mitochondrial metabolism,
a mechanism similar to that of metformin.
By studying the effects of mutations in the ADaM site, we also
ruled out that SU6656 activates AMPK by binding to that site. We
did confirm that MT 63-78 activates AMPK by binding the ADaM
site, which had been suspected (Zadra et al., 2014) but not
directly demonstrated. One surprising findingwas thatmutations
at the ADaM site not only blocked the effect of A769662 in intact
cells but also the effects of agents that increase cellular AMP/
ADP levels to promote Thr172 phosphorylation, although they
did not block allosteric activation by AMP. Thus, the effect of
AMP on net Thr172 phosphorylation requires not only intact
AMP-binding sites (Hawley et al., 2010) but also a functional
ADaM site. These results support previous findings that neither
AMP nor A769662 protected Thr172 from dephosphorylation
in heterotrimers containing N-terminally truncated b subunits
lacking the b-CBM, although allosteric activation by AMP
occurred normally (Xiao et al., 2013). Since the b-CBM forms
one surface of the ADaM-binding cleft, those constructs would
also have lacked an intact ADaM site.
While ruling out these various mechanisms for activation by
SU6656, our results point instead to a surprising mechanism in
which SU6656 binds to the catalytic site on the a subunit. By
competing with ATP, this causes acute inhibition of AMPK, yet
paradoxically simultaneously promotes phosphorylation at the
activating site, Thr172. Binding at the catalytic site is consistent
with studies showing that SU6656 inhibits numerous protein
kinases, including AMPK (Bain et al., 2007). In a structure of
CaMKIId crystallized with the compound, SU6656 was bound
in the catalytic site with its adenine-like moiety in the position
normally occupied by the adenine of ATP (Rellos et al., 2010).
We found that SU6656 inhibited both basal and AMP-stimulated
AMPK activity, suggesting that it bound at the catalytic site
rather than one of the regulatory AMP-binding sites on the g sub-
unit. Consistent with this, inhibition was competitive with ATP
and was observed in cell-free assays using the isolated a2 ki-
nase domain, but was greatly reduced by an A156T mutation
(in the CaMKIId structure [Rellos et al., 2010], the equivalent res-
idue interacts with the sulfonamide group of SU6656). Ala156
also lies at the start of the activation loop, whose conformation
is important for the binding of many kinase inhibitors; substitu-
tion of the equivalent alanine with threonine (A2016T) in the
LRRK2 kinase domain greatly reduced the potency of three
different inhibitors (Nichols et al., 2009).
Despite the acute inhibitory effect of SU6656 on AMPK kinase
activity, its binding appears to cause a conformational change
that enhances phosphorylation of Thr172 on the activation
loop by LKB1. This was not due to direct binding to LKB1, since
LKB1 activity using an alternate peptide substrate was un-
affected by SU6656. We did not observe any effect of SU6656
on inactivation of AMPK by protein phosphatases in cell-free
assays.
Recently, the biquinoline JJO-1 was reported to activate
AMPK (Scott et al., 2014b) and, since it only activated AMPK
at low ATP concentration (<100 mM), its effects initially appeared
to be competitive with ATP. However, unlike SU6656, JJO-1 did
not activate or inhibit an AMPK construct containing only the
kinase domain (a1, 1–315), suggesting that it did not bind at
the catalytic site. Also, it did not promote Thr172 phosphoryla-
tion but acted in a purely allosteric manner by binding at an un-
defined site. JJO-1 therefore acts via a different mechanism from
SU6656.
Other AMPK inhibitors, e.g., compound C, do not cause the
same paradoxical activation of AMPK as SU6656, because
they also inhibit the upstream kinases LKB1 and CaMKK2. By
searching a kinase inhibitor database, we identified another
compound, MRT199665, that was a more potent inhibitor of
AMPK than of LKB1. Like SU6656, it caused a paradoxical acti-
vation and Thr172 phosphorylation of AMPK in cells, although
its effects were much more modest. It did not affect cellular
AMP:ATP or ADP:ATP ratios, suggesting that it may act via the
same mechanism as SU6656. However, unlike SU6656,
MRT199665 inhibited rather than increased phosphorylation of
the downstream target, ACC, in intact cells.
It might seem paradoxical that compounds that bind in the
ATP-binding catalytic site and therefore inhibit the kinase should
promote activation by phosphorylation of the activation loop.
This is not unprecedented, since catalytic site inhibitors of
PKB/Akt promote its phosphorylation, both at Thr308 within
the activation loop and Ser473 within the hydrophobic motif
(Okuzumi et al., 2009). However, the inhibitors still blocked phos-
phorylation of downstream targets of Akt in intact cells, whereas
in our study SU6656 (although not MRT199665) promoted phos-
phorylation of at least one downstream target, ACC. We believe
this paradoxical activation of AMPK by inhibitors binding in the
catalytic site can be explained by assuming that inhibitor binding
causes a conformational change in the activation loop that
promotes Thr172 phosphorylation. The lifetime of the active,
phosphorylated state must then be sufficiently long to allow
dissociation of the inhibitor and its replacement by ATP, so
that one or more cycles of catalysis can occur before Thr172
dephosphorylation. The overall effect will depend on several fac-
tors, such as the turnover rate of phosphorylated Thr172 in the
cells, the off-rate of the inhibitor, and the on-rate of the target
protein at the catalytic site. The effect might be particularly
evident with substrates that bind to AMPK with high affinity
such as ACC (Scott et al., 2002), explaining why SU6656
increased the phosphorylation of ACC, but not Raptor, in intact
cells (Figure 1A). Our model also explains why SU6656 caused
a much larger Thr172 phosphorylation than berberine, yet ACC
phosphorylation was comparable. With SU6656, the effect of
increased Thr172 phosphorylation would be partly counteracted
by inhibition of catalytic activity, whereas with berberine, the in-
crease in cellular AMP would not only enhance net Thr172 phos-
phorylation but also cause allosteric activation. Thus, the same
degree of ACC phosphorylation would be achieved with a
much lower degree of Thr172 phosphorylation using berberine
rather than SU6656.
SIGNIFICANCE
Activation of AMPK by SU6656 occurs not by inhibition of
tyrosine phosphorylation of LKB1 or AMPK by Src kinases
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as previously suggested, but by binding of SU6656 at the
catalytic site of AMPK. This acutely inhibits the kinase acti-
vity, yet paradoxically causes a conformational change
that activates the kinase by promoting phosphorylation of
Thr172 on the activation loop by LKB1. This causes increased
phosphorylation of some, but not all, downstream targets in
intact cells. MRT199665 appears to act by a similar mecha-
nism to SU66556, but sorafenib activates AMPK indirectly by
inhibiting mitochondrial metabolism and increasing cellular
ADP/AMP levels. Nevertheless, this effectof sorafeniboccurs
at concentrations similar to peak plasma concentrations
observed inhumans.Our resultsaresignificantbecause there
is a current interest in the development of AMPK inhibitors for
treatment of cancer; such approaches will need to consider
thepossibility that the inhibitorsmightalsocauseparadoxical
activation by one of these two mechanisms.
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STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies and Other Probes
GAPDH Sigma-Aldrich Cat# G9545; RRID: AB_796208
pT172 (AMPK-a) Cell Signaling Technology Cat# 2531; RRID: AB_330330
pS108 (AMPK-b1) Cell Signaling Technology Cat# 4181; RRID: AB_10841303
pS792 (Raptor) Cell Signaling Technology Cat# 2083; RRID: AB_2249475
Raptor Cell Signaling Technology Cat# 2280; RRID: AB_10694695
pT202/pY204 (Erk1/Erk2) Cell Signaling Technology Cat# 4370; RRID: AB_2315112
Erk1/Erk2 Cell Signaling Technology Cat# 9107; RRID: AB_10695739
GFP Cell Signaling Technology Cat# 2956; RRID: AB_1196615
pACC1/pACC2 (S79/S212) Cell Signaling Technology Cat# 11818
AMPK, pan-a (for Western blots) Cell Signaling Technology Cat# 2532; RRID: AB_330331
AMPK-a1 (for immunoprecipitation) (Woods et al., 1996) N/A
AMPK-a2 (for immunoprecipitation) (Woods et al., 1996) N/A
AMPK-b1 (Cheung et al., 2000) N/A
AMPK-b2 (Cheung et al., 2000) N/A
SIK1 (Lizcano et al., 2004) N/A
SIK2 (Lizcano et al., 2004) N/A
SIK3 (Lizcano et al., 2004) N/A
SNARK (Lizcano et al., 2004) N/A
MARK2/3 (Lizcano et al., 2004) N/A
MARK4 (Lizcano et al., 2004) N/A
EZview Red ANTI-FLAG M2 Affinity Gel Sigma-Aldrich Cat# F2426; RRID: AB_2616449
Streptavidin DyLight 800 Conjugated Rockland Cat# S000-45
Biological Samples
AMPK, purified from rat liver (Hawley et al., 1996) N/A
Chemicals, Peptides, and Recombinant Proteins
SU6656 Sigma-Aldrich Cat# S9692
sorafenib Santa-Cruz Cat# SC-220125A
berberine chloride Sigma-Aldrich Cat# B3251
phenformin hydrochloride Sigma-Aldrich Cat# P7045
PP2 Sigma-Aldrich Cat# P0042
troglitazone Tocris-Bioscience Cat# 3114
A769662 (Goransson et al., 2007) N/A
MRT199665 (Clark et al., 2012) N/A
FuGENE 6 transfection reagent Promega Cat# E2691
PP2Ca (PPM1A) (Davies et al., 1995) N/A
GST-LKB1 (STK11) (Boudeau et al., 2003) N/A
FLAG-tagged STRAD-a (STRADA) (Boudeau et al., 2003) N/A
Myc-tagged MO25-a (CAB39) (Boudeau et al., 2003) N/A
GFP-tagged LKB1 (STK11) (Fogarty and Hardie, 2009) N/A
Human AMPK (a1b1g1 complex)
(PRKAA1:PRKAB1:PRKAG1)
generated as in (Neumann et al., 2003); gift from
Mark Peggie, University of Dundee
N/A
Human AMPK (a2b2g1 complex)
(PRKAA2:PRKAB2:PRKAG1)
generated as in (Neumann et al., 2003); gift from
AstraZeneca
N/A
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Grahame
Hardie (d.g.hardie@dundee.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
SYF cells were from the ATCC andwere usedwithin 3months of purchase. Human cells (HEK-293 andHeLa) were from the European
Collection of Cell Cultures (ECACC) and were re-validated by STR profiling by Public Health England prior to the project (certificate
dated 08/14/2015). All cells were cultured in Dulbecco’sModified Eagle’sMedium (DMEM)with 10% (v/v) FBS and 1% (v/v) penicillin/
streptomycin.
METHOD DETAILS
DNA Plasmids and Site-Directed Mutagenesis
A plasmid encoding the AMPK-a1 kinase domain (a1-KD) was made by amplifying residues 1-312 with an N-terminal FLAG-tag and
5’Kpn1 and 3’ Xho1 sites, the resulting PCR product was cloned into pcDNA5 FRT. A plasmid encoding the AMPK-a2 kinase domain
(a2-KD) was made by amplifying residues 1-310 with 5’ BamH1 and 3’ Xho1 sites, the resulting PCR product was cloned into
pGEX6P2. Point mutations were generated using the Quikchange II site-directed mutagenesis kit (Stratagene) and confirmed by
DNA sequencing.
Stable Cell Lines and Transient Transfection
HEK-293 cells stably expressing tetracycline-inducible FLAG-tagged human AMPK-g2, or an R531G mutant, were generated by
introducing the corresponding DNAs into Flp-In T-REx 293 cells (Auciello et al., 2014). Expression of the FLAG-tagged constructs
was induced for 48 hr using tetracycline (1 mg.ml-1) prior to addition of compounds under test. Transient transfections were carried
out 36-48 hr prior to experiments, using Fugene 6 according to manufacturers’ instructions.
Analysis of Commercial SU6656
Semi-preparative HPLC (see Figure S5) was performed on a Buchi PrepChrom C-700 LC system with a 250 x 21.2 mm (ID) prepar-
ative column (PrepChrom C18, 10 mm particle size, Buchi) at a flow rate of 25 mL/min. A linear gradient from 5%-95% acetonitrile in
water over 18 min was used for elution. Detection was at 254 nm and via a dual scan at 220/400 nm.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Human LKB1 purified from Sf9 cells (LKB1:
STRADa: MO25a complex) (STK11:STRADA:
CAB39)
generated as in (Jaleel et al., 2006); gift from
Division of Signal Transduction, University
of Dundee
N/A
Brij-35 (30% solution) BDH (now VWR) Cat# 224175X
phenylmethane sulphonyl fluoride Sigma-Aldrich Cat# P7626
benzamidine Sigma-Aldrich Cat# B6506
soybean trypsin inhibitor Sigma-Aldrich Cat# T9128
bovine serum albumin Sigma-Aldrich Cat# A7906
Experimental Models: Cell Lines
SYF ATCC Cat# CRL-2459
HEK-293 ECACC Cat# 85120602
Flp-In T-REx 293 ThermoFisher Scientific Cat# R78007
HeLa ECACC Cat# 93021013
Recombinant DNA
Plasmid encoding full-length human AMPK-a1 (Hawley et al., 2014) N/A
Plasmid encoding full-length human AMPK-g1 (Jensen et al., 2015) N/A
Plasmid encoding AMPK-a1 kinase domain
(a1-KD)
this paper N/A
Plasmid encoding AMPK-a2 kinase domain
(a2-KD)
this paper N/A
e2 Cell Chemical Biology 24, 1–12.e1–e4, July 20, 2017
Please cite this article in press as: Ross et al., Mechanisms of Paradoxical Activation of AMPK by the Kinase Inhibitors SU6656 and Sorafenib, Cell
Chemical Biology (2017), http://dx.doi.org/10.1016/j.chembiol.2017.05.021
NMR spectra were recorded on Bruker AVANCE II 500 spectrometer. Splitting patterns of spectral multiplets are indicated as s,
singlet; br s, broad singlet; d, doublet; dd doublet of doublets; m, multiplet. Analysis of SU 6656 supplied by Sigma: 1H NMR
(500 MHz, d6-DMSO) d 13.15 (br s, 1H), 11.30 (s, 1H), 8.05 (d, J 1.5 Hz, 1H), 8.0 (s, 1H), 7.54 (dd, J 8.0Hz, J 1.6 Hz, 1H), 7.13
(d, J 8.0 Hz, 1H), 6.76 (br s, 1H), 2.80 (m, 2H), 2.66 (s, 6H), 2.60 (m, 2H), 1.86 (m, 2H), 1.78(m, 2H). Material purified by semi-preparative
HPLC gave an identical spectrum.
LC-MS analysis was performed using a Dionex UltiMate3000 series LC instrument with aWaters Xbridge C18 column (3.5 mmpar-
ticle size, 2.1 mm x 50 mm) at a flow rate 0.3 mL/min. A linear gradient from 5%-95 % buffer B in buffer A over 8 min was used for
elution (buffer A: water/0.1% formic acid; buffer B: acetonitrile/0.1% formic acid). The LC was connected to a Bruker MicroTOF and
MS was acquired in ESI positive mode. The major peak detected by UV absorbance at 254 nm generated a m/z value ([M+H]+) of
372.4 (expected mass for C19H21N3O3S = 371.46), as well as a [2M+H]
+ peak of 743.3 (not shown).
Samples of the preparation of SU6656 received from the supplier, and that purified by semi-preparative HPLC as described above,
were dried down, dissolved in DMSO and tested for their ability to activate and trigger Thr172 phosphorylation of AMPK in HEK-293
cells. The results for both preparations were indistinguishable, once again confirming the purity of the commercial preparation
(Figure S6).
Synthesis and Analysis of MT 63-78
MT 63-78 was synthesized as described previously (Birnberg et al., 2009). LC:MS was performed on an Agilent 1100 series using a
Waters Xbridge C18 column (3.5 mmparticle size, 2.1 mm x 50mm, flow rate 0.3 mL/min, linear gradient 5%-95%buffer B in buffer A
in 7 min; buffer A: water-0.1% ammonia; buffer B: acetonitrile-0.1% ammonia); MS was by a Bruker MicrOTOF mass spectrometer.
LCMS ESI (+): Rt = 3.7 min; [M+H]
+= 327.12, expected for C21H15N2O5, 327.11. NMR spectra were recorded on Bruker AVANCE II
500 spectrometer. Splitting patterns of spectral multiplets are indicated as s, singlet; d, doublet; m, multiplet: 1H NMR (500 MHz,
CD3OD) d 8.28 (s, 1H), 8.15 (s, 1H), 8.08 (d, 2H), 7.95-7.84 (m, 4H), 7.39-7.36 (m, 1H), 6.86 (d, 2H);
13C NMR (126 MHz, CD3OD)
d 155.3, 140.5, 135.7, 135.2, 133.8, 133.0, 131.6, 128.8, 128.1, 127.5, 123.7, 117.4, 116.8, 116.5, 113.1, 107.4, 85.9.
Kinase Assays
Endogenous AMPK was immunoprecipitated using the specified antibodies (for total AMPK, an equal mixture of anti-a1 and –a2
antibodies) and assayed at 200 mM ATP (Hardie et al., 2000; Towler et al., 2008) using the AMARA peptide (Dale et al., 1995) as sub-
strate, except for assays of allosteric activation by AMP (Figure 5A) where the SAMS peptide was used as substrate with 2 mM ATP
(Gowans et al., 2013). The AMPK-related kinases SIK1, SIK2, SIK3, SNARK, MARK2/3 and MARK4 were immunoprecipitated and
assayed as previously described (Lizcano et al., 2004) in lysates of Hela cells stably expressing LKB1 (Fogarty et al., 2010). LKB1
was assayed using the LKBtide peptide as substrate (Sakamoto et al., 2004).
Assays of Phosphorylation/Dephosphorylation
Phosphorylation
Plasmids encoding FLAG-tagged AMPK- g1 (WT or RG mutant) were transfected into HeLa cells using Fugene 6. Cell lysate (90 mg
protein) was immunoprecitated using EZview Red anti-FLAG M2 affinity gel, and incubated for 10 min in a total volume of 75 ml with
200 mMATP, 5 mMMgCl2 ± a limiting amount of LKB1:STRAD:MO25 complex (0.7 mg), in the presence or absence of AMP (200 mM)
or SU6656 (3 mM) as indicated. The reaction was terminated by addition of 1 ml of ice-cold IP buffer (50 mM Tris/HCl, pH 7.4 at room
temp, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 5 mM Na pyrophosphate, 50 mM NaF, 1 mM dithiothreitol, 0.1% (v/v) Triton X-100,
0.1 mM phenylmethane sulphonyl fluoride, 5 mg/ml soybean trypsin inhibitor, 1 mM benzamidine, and after an additional wash in the
same buffer the AMPK activity or Thr172 phosphorylation status was determined by kinase assay or Western blotting.
Dephosphorylation
Active human AMPK (a1b1g1 complex) phosphorylated on Thr172 was generated as described previously (Hawley et al., 2012).
Dephosphorylation assays contained AMPK, 2 mM AMP or various concentrations of SU6656, 5 mM ATP, 1 mg/ml bovine serum
albumin and 60 mg/ml PP2Ca in Hepes buffer (50 mM Na Hepes, pH 7.4, 150 mM NaCl, 1 mM dithiothreitol, 0.02% (w/v) Brij-35).
The reaction was started by adding MgCl2 (9.8 mM) to activate PP2Ca; reactions were conducted in a shaking incubator at 30
C
for 10 min and were stopped by diluting 5 ml into 300 ml Hepes buffer (as above). An aliquot (5 ml) was then taken to assay AMPK.
Measurement of AMP:ADP and ADP:ATP Ratios
The levels of AMP, ADP and ATPweremeasured using a TSQQuantiva interfacedwith Ultimate 3000 Liquid Chromatography system
(ThermoScientific), equipped with a porous graphitic carbon column (HyperCarb 30x1mm ID 3 mm; Part No: C-35003-031030,
Thermo-Scientific). Mobile phase buffer A consisted of 0.3% (v/v) formic acid adjusted to pH 9 with ammonia prior to a 1:10 dilution.
Mobile phase buffer B was 80% (v/v) acetonitrile. The column was maintained at a controlled temperature of 30C and was equili-
brated with 10% buffer B for 5 minutes at a constant flow rate of 0.06 mL/min. Aliquots of 1 mL of each sample were loaded onto the
column and compounds eluted with a linear gradient of 10%-60% buffer B over 9 min. Buffer B was then increased to 100% within
1 min, and the column washed for 5 min with 100% Buffer B. Eluents were sprayed into the TSQ Quantiva using Ion Max NG ion
source with ion transfer tube temperature set to 350C and vaporizer temperature 125C. The TSQ Quantiva was run in negative
mode with a spray voltage of 2600, sheath gas 40 and Aux gas 10. Levels of ATP, ADP and AMP were measured using multiple
reactions monitoring mode (MRM) with optimised collision energies and radio frequencies previously determined by infusing pure
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compounds. Three transitions were used to monitor each of the three compounds, ATP (505.92>158.98, 505.92>408.12 and
505.92>426.12), ADP (426.98>158.98, 426.98>328.78 and 426.98>409.09) and AMP (345.96>134.20, 345.96>151.27 and
345.96>211.12).
Measurements of Cellular Oxygen Consumption
Cellular oxygen consumption rate was measured using a Seahorse XF24 Extracellular Flux Analyser according to manufacturers’
instructions, as specified previously (Hawley et al., 2010).
Curve Fitting
Data were fitted to the specified equations by non-linear regression using GraphPad Prism 6 for Mac OSX.
Other Analytical Procedures
SDS-PAGE was performed using precast Bis-Tris 4–12% gradient polyacrylamide gels in the MOPS buffer system (ThermoFisher
Scientific). Proteins were transferred to nitrocellulose membranes using the iBlot 2 system (ThermoFisher Scientific). Membranes
were blocked for 1 hr in Li-Cor Odyssey blocking buffer. The membranes were probed with appropriate antibody (0.1–1 mg/ml) in
TBS-Tween and 2% (w/v) non-fat dried skimmed milk except where the blotting enhancement system was used (as per manufac-
turers’ instructions). Detection was performed using secondary antibody (1 mg/ml) coupled to IR 680 or IR 800 dye, and the mem-
branes were scanned using the LICOR Odyssey IR imager. Protein concentrations were determined by Coomassie Blue binding
with bovine serum albumin as standard (Bradford, 1976). The ArnA contaminant in the human a1b1g1 complex expressed in
E. coli was identified by peptide mass fingerprinting.
QUANTIFICATION AND STATISTICAL ANALYSIS
Numbers of replicates and statistical significance is indicated in Figures or Figure legends. Numbers of replicates (n) refer to
biological replicates, i.e. the number of independent cell cultures analyzed or independent cell-free assays conducted. Significances
of differences were estimated with GraphPad Prism 6 for Mac OSX, using 1-way or 2-way ANOVA as appropriate, and (unless
stated otherwise) Sidak’s multiple comparison test. Significant differences are indicated either by asterisks: *P<0.05, **P<0.01,
***P<0.001, ****P<0.0001, or by daggers: yP<0.05, yyP<0.01, yyyP<0.001, yyyyP<0.0001.
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